Depatuxizumab mafodotin
- Generic Name
- Depatuxizumab mafodotin
- Drug Type
- Biotech
- CAS Number
- 1585973-65-4
- Unique Ingredient Identifier
- F3R7A4P04N
- Background
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
- Indication
No approved indication.
UNITE Study: Understanding New Interventions With GBM ThErapy
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Steroid eye dropsDrug: Vasoconstrictor eye dropsOther: Cold compressRadiation: RadiationDrug: Ophthalmic steroid ointment
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT03419403
- Locations
- 🇩🇪
Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany
🇺🇸Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States
🇳🇱Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands
Expanded Access to ABT-414
- Conditions
- Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03123952
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
- Conditions
- Transformed Lymphoma / DLBCLDiffuse, Large B-Cell, LymphomaFollicular Lymphoma, Grade 3b
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02855359
- Locations
- 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3bFollicular Lymphoma, Grade 3b
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02592876
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
- Conditions
- Malignant GliomaGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2015-10-29
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 53
- Registration Number
- NCT02590263
- Locations
- 🇯🇵
University of Tsukuba Hospital /ID# 140433, Tsukuba-shi, Ibaraki, Japan
🇯🇵Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan
🇯🇵Iwate Medical University Hospital /ID# 149145, Shiwa-gun, Iwate, Japan
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 691
- Registration Number
- NCT02573324
- Locations
- 🇺🇸
Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States
🇺🇸Emory Midtown Infectious Disease Clinic /ID# 144015, Atlanta, Georgia, United States
🇺🇸University of Pennsylvania Medical Center - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 266
- Registration Number
- NCT02343406
- Locations
- 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 202
- Registration Number
- NCT01800695
A Safety Study of SGN-CD19A for B-Cell Lymphoma
- Conditions
- Lymphoma, FollicularLymphoma, Large B-Cell, DiffuseBurkitt LymphomaPrecursor B-cell Lymphoblastic Leukemia-LymphomaLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01786135
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
- Conditions
- Precursor B-cell Lymphoblastic Leukemia-LymphomaBurkitt Lymphoma
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01786096
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸All Children's Hospital, Saint Petersburg, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.